维普期刊资源整合服务平台（V6.5）

74篇 您的检索式：作者名="Graham BS"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	Day 3 morphology is a poor predictor of blastocyst quality in extended culture 显示文摘	James Graham MS Taer Han BS Richard P	2000	Fertil Stefil2000，74，3：	1
2	Safety and immuno- genicity of Env2-3, a human immunodeficiency virus type I candi- date vaccine, in combination with a novel adjuvant, MTP- PE/ MF59显示文摘	Keefer MC Graham BS McElrath M J	1996	AIDS Res Hum Retroviruses1996，12，8：	1
3	Cobb syndrome associated with a verrucous(angiokeratomalike)vascular malfomation显示文摘	Clinton TS Cooke LM Graham BS		0，，：	1
4	Viral and host factors in human respiratory syncytial virus pathogenesis显示文摘	Collins PL Graham BS	2008	J Virol2008，82，5：	1
5	Reiter's syndrome显示文摘	Schneider JM Matthews JH Graham BS	2003	Cutis2003，71，3：	1
6	Novel antigens forRSV vaccines显示文摘	Graham BS Modjarrad K Mclellan JS	2015	Curr Opin Immunol2015，35，：	1
7	Inhibition of respiratory syncytial virus by RhoA-derived peptides:Implications for the development of improved antiviral agents targeting heparin-binding viruses显示文摘	Budge PJ Graham BS	2004	J Antimicrob Chemother2004，54，2：	1
8	An in vivo and in vitro study of the loss of plasticizer from soft polymer-gel materials显示文摘	Jones DW Sutow FJ	1991	J Dent Res1991，70，5：	1
9	RhoA interacts with the fusion glycoprotein of respiratory syneytial virus and facilitates virus-in- duced syncytium formation显示文摘	Pastey MK Crowe JE Jr Graham BS	1999	J Virol1999，73，9：	1
10	Safety and tolerability of chikungunya virus-like particle wtccinc in healthy adults: a phase 1 dose-escalation trial 显示文摘	Chang 1-3 Dowd KA Mcndoza FH Saundcrs JG Sitar S Plummet SH Yamshchikov G Sarwar UN Hu Z Enama ME Bailer RT Koup RA Schwartz RM Akahata W Nabel GJ Mascola JR Pierson TC Graham BS Ledgerwood JE VRC 311 Study Team	2014	Lancet2014，384，9959：	1
11	Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers显示文摘	Budge PJ Lebowitz J Graham BS	2003	Antimicrob Agents Chemother2003，47，11：	1
12	Biological challenges and technological opportunities for respiratory syncytial virus vaccine development显示文摘	Graham BS	2011	Immunol Rev2011，239，1：	1
13	Correlates of protective immunity for Ebola vaccines : implications for regulatory approval by the animal rule 显示文摘	Sullivan NJ Martin JE Graham BS	2009	Nat Rev Microbiol2009，7，：	1
14	Smallpox vaccines:Past,present,and future显示文摘	Parrino J Graham BS	2006	J Allergy Clin Immunol2006，118，6：	1
15	Nutritional absorption in short bowel syndrome显示文摘	Graham M. Woolf MD Cindy Miller RPDP Regina Kurian RT Dr. Khursheed N. Jeejeebhoy MB BS PHD	1987	Digestive Diseases and Sciences1987，，1：	1
16	Phase 2 study of an HIV-1 canarypox vaccine (vCPI452) alone and in combination with rgpl20: negative results fail to trigger a phase 3 correlates trial 显示文摘	Russell ND Graham BS Keefer MC	2007	J Acquir Immune Defic Syndr2007，44，2：	1
17	TLR9 agonist, but not TLRT/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity 显示文摘	Johnson TR Rat S Seder RA Chen M Graham BS	2009	Vaccine2009，27，23：	1
18	Lessons from failure-preparing for future HIV-1 vaccine efficacy trials显示文摘	Graham BS Mascola JR	2005	J Infect Dis2005，191，5：	1
19	Correlates of protective immunity for Ebola vaccines:implications for regulatory approval by the animal rule显示文摘	Sullivan NJ Martin JE Graham BS	2009	Nat Rev Microbiol2009，7，5：	1
20	Conditional genotypic probabilities for microsatellite loci显示文摘	Graham J Curran J Weir BS	2000	Genetics2000，155，4：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示